- Home
- News
- latamerica
- infectious disease testing
Infectious Disease Testing Articles & Analysis
26 news found
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
XPhyto is investigating the potential application of one or more of its ODF biosensor screening tests for oral inflammation to detect buprenorphine-related dental problems. ...
The new team members bring skill sets and experience that will support the commercial launch of its blood testing ecosystem, which reimagines blood testing from collection to sample preparation to analysis, to better meet the needs of the modern clinician and consumer. ...
Infectious disease testing (including sepsis) is one of the fastest growing molecular diagnostic segments representing approximately $2 billion globally per year. ...
Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch of its new B2C e-commerce website, abingdonsimplytest.com. ...
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB). ...
Theoretically, the 50% cytotoxic concentration (CC50) is the concentration of test compound required to reduce cell viability by 50%. Cytotoxicity of test compounds is best determined simultaneously with uninfected cells to obtain a 50% cytotoxic concentration (CC50) value. Cytotoxicity tests use proportionally increasing concentrations of the ...
Currently, 32 districts are in the process of onboarding the testing solution, and more are expected to join. With involvement in more than 50 percent of worldwide testing, Thermo Fisher is the leading single-source supplier in COVID-19 testing. ...
“The award of this Phase II contract from NCI validates our work on development of the liver fluke test and is a major step forwards for Kephera Diagnostics, advancing our mission to improve diagnostics for people affected by emerging and neglected infectious diseases worldwide” said Dr. ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and ...
ASHI 2021 -- At the annual meeting for the American Society for Histocompatibility and Immunogenetics (ASHI) this week, Thermo Fisher Scientific announced two new additions to its transplant diagnostics portfolio. These new products will enable transplant laboratories to better characterize samples and bring speed and confidence to the transplant laboratory. More than 100,000 adults are now on a ...
A $7.5 million commitment for the 2021-2022 school year will once again provide diagnostic instruments, test kits and related supplies. "A year after we launched The Just Project, COVID-19 cases are increasing again, and testing is critical to ensuring campus safety," said Fred Lowery, senior vice president and president for customer channels at Thermo Fisher ...
The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in ...
The test will be available as a service through Kephera’s CLIA-certified laboratory. ...
(Alveo) announced today that it has been named a winner of the $6M XPRIZE Rapid COVID Testing Competition for its be.well COVID-19 Test. The be.well™ platform provides individuals access to molecular testing and cloud-based analytics for rapid diagnosis and management of infectious diseases. ...
Mesa Biotech has developed the Accula System, an affordable, easy-to-use, point-of-care PCR-based testing platform for infectious disease diagnosis. The platform enables rapid, highly accurate testing at physician offices, pharmacies and other settings, providing results in 30 minutes. Beyond COVID-19 testing, ...
Smiths Detection, a global leader in threat detection and security screening technologies, today reports that its BioFlash Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). The tests were performed ...
Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. ...
As the first of its kind platform, be.well™ is as accurate as a PCR test with all the benefits of an antigen test in terms of cost and accessibility that yields rapid test results via smartphone connectivity. ...
Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), to complete the development and launch of a new test for Zika virus infection. ...